References for Flavay® Articles

1. Masquelier J. Plant extract with a proanthocyanidins content as a therapeutic agent having radical scavenging effect and use thereof. U.S. Patent No. 4,698,360, 1987.
2. Masquelier J. A lifetime devoted to OPC and pycnogenols. Alfa Omega Editrice, Pub. 1996.
3. Schwitters B. Masquelier, J. OPC in practice. Alfa Omega Editrice, Pub., 1995.
4. Schwitters B. Dr. Masquelier's mark on health. Alfa Omega Editrice, Pub., 2004.
5. Kilham C. Masquelier, J. OPC: The miracle antioxidant. Keats Pub., Inc. 1997.
6. Masquelier J. Pycnogenols: recent advances in the therapeutical activity of procyanidins. Natural Products as Medicinal Agents, Vol. 1, Hippokrates Verlag, Stuttgart, pp. 243-256, 1981.
7. Watson RR (eds), et al. Polyphenols in Human Health and Disease. Academic Press; Ed. 1 (2013).
8. Passwater RA, et al. Pycnogenol super 'protector' nutrient. Keats Pub., Inc. 1994.
9. Barilla J, et al. The nutrition superbook: volume 1: the antioxidants. Keats Pub., Inc. 1995.
10. Packer, L, et al. The antioxidant miracle: your complete plan. John Wiley & Sons, Inc. 1999.
11. Lieberman, S, et al. The real vitamin & mineral book: going beyond the RDA. Avery Pub. 1990.
12. Mindell, E, et al. Earl Mindell's vitamin bible for the 21st century. Warner Books, Inc. 1999.
13. Braverman, E, et al. The healing nutrients within: in facts, findings and new research. Keats, 1987.
14. Lombard, J. (board certified neurologist), et al. The brain wellness plan - breakthrough medical, nutritional and immune-boosting therapies to prevent and treat depression, alzheimer's disease, chronic fatigue syndrome, attention deficit disorder, multiple sclerosis, parkinson's disease, lou gehrig's disease. Kensington Pub. Corp. 1998.
15. Carper J. Miracle cures: dramatic new scientific discoveries revealing the healing powers of herbs, vitamins, and other natural remedies. HarperCollins Pub., 1998.
16. Philpott, WH, et al. Brain Allergies: The Psychonutrient Connection, Keats Pub., 1980.
17. Journal of the American Medical Association report on meeting of experts on the subject of food and behavior. Conclusions from this conference were summarized as follows: dietary pharmacology is no longer at the fringe of medicine...foods do affect behavior. Foods do affect the brain. JAMA 254:4, Dec. 27, 1985.
18. Masquelier J, et al. Stabilization of collagen by procyanidolic oligomers. Acta Therap 7:101-5, 1981.
19. Tixier, J.M, et al. Evidence by in vivo and in vitro studies that binding of pycnogenols to elastin affects its rate of degradation by elastases. Biochem Pharmacol, 33:3933-9, 1984.
20. Masquelier, J. Aspects pharmacologiques nouveaux de certains flavonoides. A Vie Medical 12:1969.
21. Laparra, J, et al. Etude pharmaco-cinetique des oligomers procyandoliques totaux du raisin. Acta Therapeutica, 4, 1978.
22. Laparra, J, et al. Etude pharmacocinetique des oligomeres flavonoliques. Plantes med et phyto, Tome XI, pp. 133-142, 1977.
23. Robert AM, et al. Etude de l'action des oligomeres procyanidoliques sur des cellules mesenchymateuses en culture. II l'attachment des fibres elastiques aux cellules. (Study of the effect of procyanidolic oligomers on mesenchymal cells in culture II. Attachment of elastic fibers to the cells.) Pat Biol (30)6:601-7, 1990.
24. Facino RM, et al. Free radical scavenging action and anti-enzyme activities of procyanidines from Vitis vinifera. A mechanism for their capillary protective action. Arzneimittelforschung, 44: 592-601, 1994.
25. Kuttan R, et al. Collagen treated with catechin becomes resistant to the action of mammalian collagenase. Experientia, 37: 221-223, 1981.
26. Porter, Lawrence J. Wong Rosalind Y. Chan, Bock G. The molecular and crystal structure of (+)-2,3-trans-3,4-trans-leucocyanidin [(2r,3s,+r)-(+)-3,3', 4.4', 5.7'-Hexahydroxyflavan] dihydrate, and comparison of its heterocyclic ring conformation in solution and the solid state. Journal of the Chemical Society; Perkin Transactions I 1985. pp. 1413-17.
27. Masquelier, J. Proanthocyanidins et radicaux libres (Radical scavenger effect of proanthocyanidins), 1985.
28. Uchida S, et al. Condensed tannins scavenge active oxygen free radicals. Med Sci Res, (15) 1987. pp. 831-832.
29. Ariga, T. Radical scavenging action and its mode in procyanidins b-1 and b-3 from azuki beans to peroxyl radicals. Agric Biol Chem, 54(10) 1990. pp. 2499-2504.
30. Da Silva R, et al. Radical scavenger capacity of different procyanidins from grape seeds. Presented at a symposium, "Free radicals in biotechnology and medicine." Royal Society Of Chemistry, London January 1990, pp. 79-80.
31. Bauman J, et al. "Hemmung der prostagladinsynthetase durch flavonoide und phenolderivate im vergleich nit deren 02 radikalfangereigenschaften" Arch Pharm, (Weinheim) 313 (1980) pp. 330-337.
32. Facino RM, et al. Free radical scavenging action and anti-enzyme activities of procyanidines from vitis vinifera. A mechanism for their capillary protective action. Arzneimittelforschung, 44: 592-601, 1994.
33. Nuttall SL, et al. An evaluation of the antioxidant activity of a standardized grape seed extract. j Clin Pharm Ther 1998;23:135-40.
34. Masquelier J. Procyanidolic oligomers. J Parums Cosm Arom, 95: 89-97, 1990.
35. Kakegawa H, et al. Inhibitory effects of tannins on hyaluronidase activation and the degranulation from rat mesentry mast cells. Chem. Pharm. Bull. 33(11)5079, 1985.
36. Harmand MF, et al. The fate of total flavanolic oligomers extracted from 'vitus vinifera l.' in the rat. European Journal of Drug Metabolism and Pharmaccokinetics. 1978, No. 1 pp. 15-30.
37. Delrieu P, et al. Free-radical scavenging activity of proanthocyanidolic oligomers encapsulated in glycospheres: an in vivo and in vitro study. Cosmetology Department & S Biovectors, Ramonville St. Agne France. pp. 1-9.
38. Meunier MT, et al. Inhibition of angiotensin i converting enzyme by flavanolic compounds: in vitro and in vivo studies. Planta Medica, May 26, 1986. pp. 12-15.
39. Kim J, et al. Effect of select antioxidants on malondialdehyde modification of proteins. Nutrition, Nov-Dec;16(11-12):1079-81, 2000.
40. Barbier A, et al. Activite angioprotectrice des oligomeres procyanidolques chez l'animal-activite aniagoniste vis-a-vis des mediateurs de l'inflamation. Sanofi Res Toul Cedex Fr, pp. 31-40. (1989)
41. Dubos C, et al. Evolution de la resistance capillaire, spontanement ou artificiellement diminuee par l'action d'une substance capillaro-toxique chez des personnes agees--action benefique d'un agnet actif sur la micro-circulation: l'Endotelon. Inform. Therapeut. 1980. pp. 302-305.
42. Dartenuc JY, et al. Resistance capillaire en geriatrie etude d'un microangioprotecteur-Endotelon. (Capillary resistance in geriatrics trial of a microvascular protective agent Endotelon.) Bordeaux Med. 13:903-7, 1990.
43. Lagrue G, et al. Etude des effets des oligomeres du procyanidol sur las resistance capillaire dand l'hypertension arterielle et certaines nephropathies. Sem Hosp Paris 18-25 Septembre, 1981.
44. Beylot C, et al. Essai therapeutique d'un angioprotecteur peripherique, l'Endotelon. Actualite Therapeutique Gaz. Med. de France (87)22:2919-24, 1980.
45. Lesbre FX, et al. Effect de l'Endotelon sur l'indice de fragilite capillaire dan une population specifique: les sujets cirrhotiques. (Effect of endotelon on the capillary fragility index in a specific group: cirrhotic subjects.) Gaz Med France 90:24332-24337, 1983.
46. Sarrat L. Abord therapeutique des troubles fonctionnels des membres inferieurs par un microangioprotecteur l'Endotelon. (Therapeutic approach to functional disorders of lower extremities.) Bordeaux Med, 11:685-8, 1981.
47. Delacroix P. Etude en double aveugle de l'Endotelon dans l'insuffisance veineuse chronique. (Double-blind study of endotelon in chronic venous insufficiency.) Ther. La Revue de Medecine 31:1793-1802, 1981.
48. Thebault J, et al. Etude de l'Endotelon dand les manifestations fonctionnelles de l'insuffisance veineuse peripherique-resultats d'une etude en double aveugle portant sur 92 patients. (Study of endotelon in functional manifestations of peripheral venous insufficiency. Results of a double-blind study on 92 patients.) Gazette Medicale (Montr) 92:12, 1985.
49. Wegrowski J, et al. The effect of procyanidolic oligomers on the composition of normal and hypercholesterolemic rabbit aortas. Biochem Pharmacol 33:3491-7, 1984.
50. Chang WC, et al. Inhibition of platelet aggregation and arachidonate metabolism in platelets by procyanidins. Prostagland Leukotri Essent Fatty Acids, 38:181-8, 1989.
51. Masquelier, J. pycnogenol: recent advances in the therapeutical activity of procyanidins. Supplement of Planta Medica, Journal of Medicinal Plant Research and Journal of Natural Products, July 1980 pp. 243-256.
52. Henning B, et al. Lipid peroxidation and endothelial cell injury: implications in atherosclerosis. Free Rad Path & Med, (4)1988 pp. 99-106.
53. Fitzpatrick DF, et al. Endothelium-dependant vascular effects of french maritime pine bark extract. J Cardiovas Pharmacol 1998;32:505-515.
54. Gazave JM. "Notions recentes sur les capillaires" unpub. bulletin from the Laboratoire De Physiologie Patholigie pp. 26-29.
55. Ruf JC. Wine and polyphenols related to platelet aggregation and atherothrombosis. Office International Vigne et du Vin, Nutrition and Health Unit, Paris France; Drugs under Experimental and Clinical Research (Switz.) 25/2-3 (125-131), 1999.
56. Blazso G, et al. M. Oedema-inhibiting effect of procyanidin. Acta Physiologica Academiae Scientiarum Hungaricae, Tomus 1980;56(2):235-240.
57. Tayau MF, et al. Action du leucocyanidol sur l'hyalaluronidase. Bull Soc Pharm Bordeaux, 95:132-136, 1956.
58. Lamy M. Utilization des oligomeres procyanidoliques en gynecologie. Essai Therapeutique Tomel (14) Sept. 2, 1981. pp. 1021-22.
59. Henriet J. Venous and lymphatic insufficiency 4729 patients receiving hormone therapy and procyanidin oligomers. Phlebologie 46:313-25, 1993.
60. Pfister, A., Simon, M.T., Gazave, J.M. Sites de fixation des oligomeres procyanidoliques dans la paroi des capillaires sanguins du poumon decobaye. Acta Therapeutica (8) 1982. pp. 223-237.
61. Kuttan, R., Donnelly, P., Di Ferrante, N. "Collagen treated with (+) -catechin becomes resistant to the action of mammalian collagenase." Laboratory of Connective Tissue Research, Dept. of Biochem. Baylor Col. of Med., Houston TX. 28, May, 1980.
62. Gendre, P., Laparra, J., Barraud, E. "Effect protecteur des oligomeres procyanidoliques sur le lathyrisme experimental chez le rat." Ann. Pharm. Francaises, (43)1, 1985 pp. 61-73.
63. Corbe C, et al. Light vision and chorioretinal circulation. Study of the effect of procyanidolic oligomer (Endotelon). Jn. Fr. Ophthalmol, (11)5:453-460, 1988.
64. Boissin JP, et al. Chorioretinal circulation and dazzling: use of procyanidol oligomers (Endotelon). Bull Soc Ophtalmol Fr, 88(2):173-4, 177-9, 1988.
65. Proto F, et al. Electrophysical study of vitis vinifera procyanoside oligomers effects on retinal function in myopic subjects. Ann Ott Clin Ocul, 114:85-93, 1988.
66. Saracco, JB, et al. Etude d l'Endotelon en Ophthalmologie. Gaz Med de France, 88:2035-2038, 1981.
67. Scharrer A, et al. Anthocyanosides in the treatment of retinopathies. Klin Monatsbl Augenheilkd, 178:386-389, 1981.
68. Corbe C, et al. Microangiopathy of the retina. J. Fr. Ophthalmol, 11:453, 1988.
69. Verin MM, et al. Retinopathies et O.P.C. (Retinopathy and OPC) Bord Med 1978;11:1467-1474.
70. Soyeux A, et al. Endotelon, diabetique et hemorhelogie. (Diabetic retinopathy and hemorheology.) Bull Soc Ophtalmol Fr. 87(12):1441-4, 1987.
71. Froantin M. Les oligomeres procyanidoliques dans le traitement de la fragilite capillaire et de la retinopathie chez les diabetiques. A propos de 26 cas. (Procyanidolic oligomers in the treatment of capillary fragility and retinopathy in diabetics.) Med Int 16:432-434, 1981.
72. Arne JL. Contribution a l'etude des oligomeres procyanidoliques: Endotelon, dans la retinopathie diabetique (a propos de 30 observations). Gaz. Med. de France, Vol. 89, No. 30, Oct. 8, 1982.
73. Baruch J. Effect of Endotelon in postsurgical edema. Results of a double-blind study versus placebo in 32 female patients. Ann Chir Plast Esthet 29(4):393-5, 1984.
74. Rao CN, et al. Influence of bioflavonoids on the collagen metabolism in rats with adjuvantinduced arthritis. Ital J Biochem. 30:54-62, 1981.
75. Gabor, M. Pharmacologic effects of flavonoids on blood vessels. Angiologica, 9:355-374, 1972.
76. Havsteen, B. Flavonoids, a class of natural products of high pharmacological potency. Biochem Pharmacol, 32:1141-48, 1983.
77. Reimann HJ, et al. Histamine and acute haemorrhagic lesions in rat gastric mucosa: prevention of stress ulcer formation by (+)-cate-chin, an inhibitor of specific histidine decarboxylase in vitro. Berkhauser Verlag, Vol. 7/1, Univ. of Marburg/Lahn, Ger., 1977.
78. Masquelier J. Action protectrice du vin sur l'ulcère gastrique. Recherches subventionnées par la Conseil Interprofessional du Vin de Bordeaux. 59-62.
79. Amella, M., et al. Inhibition of mast cell histamine release by flavonoids and bioflavonoids. Planta Medica, 5116-20, 1985.
80. Shaw, R. How pycnogenol Helps Sports People (Australia).
81. Masquelier, J. Procyanidolic oligomers (leucocyanidins). Parfums Cosmet Arom 1990;95:89-97.
82. Pecking A, et al. Oligomeric proanthocyanidins (Endotelon) in the treatment of post therapeutic lymphedema of the upper limbs. Int'l d'Antiologie, Toulouse, France, Oct 4-7, 1989;69-73.
83. Laparra J, Michaud J, Masquelier J. Action des oligomeres procyanidoliques sur le cobaye carence en vitamine c. Travaux Originaux, Laboratoire de Matiere Medicale, Faculte de Phamacie de Bordeaux, University of Bordeaux, 1979.
84. Masquelier, J. Action comparee de divers facteurs vitaminiques P sur l'oxydation de l'acide ascorbique par les ions cuivriques. Bulletin de la Societe se Chimie Biologique. 1951:33(3-4):302-305.
85. Masquelier, J. Action comparee de divers facteurs vitaminiques p sur l'acide ascorbique-oxydase. Bull. de la Societe de Chimie Biologique XXXIII (3,4) 1951. pp.304-306
86. Kakegawa, H., Matsumoto, H., Endo, K., Satoh, T., Nonaka, G., Mishioka, I. "Inhibitory effects of tannins on hyaluronidase activation and on the degranulation from rat mesentery mast cells." Chem. Pharm. Bull. 33(11)1985. 5079-5082.
87. Reiman, HJ, et al. Histamine and acute haemorrhagic lesions in rat gastric mucosa: prevention of stress ulcer formulation by (+)-catechin, an inhibitor of specific histidine decarboxylase in vitro. Dirkhauser Verlag, Vol 7/1, 1977.
88. Pariente J. Post-traumatic edemas in sports: a controlled test of endotelon. Gaz Med France 90:231-6, 1983.
89. Masquelier J, et al. Flavonoides et pycnogenols. Int J Vit Nut Res 1979;(49)3:307-311.
90. Yu C, et al. Mutagenicity of proanthocyanidins. Food Chem Toxicol 1987;25(2):135-140.
91. Pantaleoni GC, et al. Univerisity of Aquila Pharmacol-Toxicologica Report, 1971.
92. Laparra J, et al. Etude pharmacocinetique des oligomers procyandoliques totaux du raisin (endotelon), Acta Therapeutica, 4:233, 1978.
93. Volkner, Wolfgang Muller, Ewald, Micronucleus assay in bone marrow cells of the mouse with pycnogenol. Cytotest Cell Research GmbH & Co., projects 143010, 143021; Feb 1989.
94. Acute and chronic toxicity tests. International Bio-Research, Inc. Hanover, Germany, 1967-1971.
95. Dumon, M., Michaud, J., Masquelier, J. Proanthocyanidin content in vegetable extracts to be used in the preparation of medicines. Bull. Soc. Pharm. Bordeaux, 129:51-65, 1990.
96. The International Nutrition Company Special Report, Pine vs. Pine Comparative Analysis between Masquelier's Original Pine Bark OPCs and another leading brand pine bark extract, Oc. 1998. PhytoChem Technologies, Inc., Chelmsford, Massachusetts, Ju. 1998. The International Nutrition Company Special Report, Masquelier's Original OPCs and ten grape seed extracts; an independent, reproducible state-of-the-art comparative analysis, No. 1997.
97. Feine-Haake, G. A new therapy for venous diseases. Zeitschrift fur Allgemeinmedizin 839 (June 30, 1975).
98. Gabor, Miklos, Razga, pycnogenol inhibits inflammation in a dose-dependant manner. Acta. Physiol. Hung. 77:197-207 (1991).
99. Dartenus, et al. Bordeaux Med. 13:903 (1980).
100. Biard, L. Evaluation d'une nouvelle therapeutique par la mesure de la resistance capillaire conjuctivale. Medicin Praticienne. 786, 62-66 (1980).
101. Baracco, et al. Gaz Med. de France 88:2035 (1981).
102. Cahn J, et al. Etude de L'administration d'oligomeres procyanidoliques chez le rat. (Administration of procyanidolic oligomers in rats. Observed effects on changes in the permeability of the blood brain barrier.) Semaine des Hopitaux 59:2031-4, 1983.
103. Rohdewald, P. Pycnogenol. Flavonoids in Health and Disease (Rice-Evans C and Packer L, eds.) Dekker, New York. 1998;404-419.
104. Meunier MT, et al. Activite antiradicalaire d'oligomeres procyanidolique et d'anthocyanosides vis-a-vis de l'anion superoxyde et vis-a-vis del la lipoperoxydation. (Free-radical scavenger activity of procyanthocyanidolic oligomers and anthocyanosides with respect to superoxide and lipid peroxidation.) Plant Med Phytother 23(4):267-274, 1989.
105. Dubos, G., et al. Evolution de la resistance capillaire, spontanement ou artificiellement diminuee par l'action d'une substance capillaro-toxique chez des personnes agees. La Revue de la Geriatrie, Tome 5, no. 6, Sept. 1980.
106. Kidd PM. A review of nutrients and botanicals in the integrative management of cognitive dysfunction. Altern Med Rev 1999 Jun;4(3):144-61.
107. Crook, T.H. The PS Factor: the key to peak mental performance for life. Mind Pub. Inc., 1999.
108. Kidd, P.M. Phosphatidylserine (PS): A Remarkable Brain Cell Nutrient, Lucas Meyer, Inc. Third Edition April 1998.
109. Klinkhammer P, et al. Effect of phosphatidylserine on cerebral glucose metabolism in Alzheimer's disease. Dementia. 1990;1(4):197-201.
110. Milenkovic, D, et al. Dietary Flavanols Modulate the Transcription of Genes Associated with Cardiovascular Pathology without Changes in Their DNA Methylation State. PLoS One. 2014; 9(4): e95527. doi: 10.1371/journal.pone.0095527.
111. Hershkowitz M, et al. Long-term treatment of dementia of Alzheimer type with Phosphatidylserine: Effect on cognitive functioning and performance in daily life. In Phospholipids in the Nervous System: Biochemical and Molecular Pathology. N.G. Bazan, L.A. Horrocks, G.Toffano (eds). Liviana Press, Padova 1989, 279 – 288.
112. Kidd, P.M. Phosphatidylserine (PS): A Remarkable Brain Cell Nutrient, Lucas Meyer, Inc. Third Edition April 1998.
113. Masquelier, J. Effets physiologiques du vin. Sa part dans l'alcoolisme. Bulletin de l'O.I.V. 1988:(689-690):555-578.
114. Cenacchi T, et al. Cognitive decline in the elderly: A double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Aging, 1993;5:123–133.
115. Maggioni M, et al. Effects of phosphatidylserine therapy in geriatric patients with depressive disorders. Acta Psychiatr Scand. 1990;81:265–270.
116. Brambilla F, et al. Beta-endorphin concentration in peripheral blood mononuclear cells of elderly depressed patients—effects of phosphatidylserine therapy. Neuropsychobiology, 1996;34:18–21.
117. Monteleone P, et al. Blunting by chronic phosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men. Eur J Clin Pharm, 1992;43:385–388.
119. Funfgeld EW, et al. Double-blind study with phosphatidylserine (PS) in parkinsonian patients with senile dementia of Alzheimer's type (SDAT). Prog Clin Biol Res, 1989;317:1235-46.
120. Fernholz KM, Seifert JG, Bacharach DW, Burke ER, Gazal O: The Effects of Phosphatidyl Serine on Markers of Muscular Stress in Endurance Runners. Med Sci Sports Exerc 2000, 32(5):S321.
121. Fahey TD, et al. The Hormonal and Perceptive Effects of Phosphatidylserine Administration During Two Weeks of Weight Training-Induced Over-Training. Biol Sport 1998, 15(2):135-144.
122. Crook, TH, et al. Effects of Phosphatidylserine in Alzheimer's Disease. Psychopharmacol Bull 1992;28(1):61-66.
123. Engel R.R., Double-blind cross-over study of phosphatidylserine vs. placebo in patients with early dementia of the Alzheimer type. Eur Neuropsychopharmacol 1992 Jun;2(2):149-55.
124. Monteleone P., et al. Effects of phosphatidylserine on the neuroendocrine response to physical stress in humans. Neuroendocrinology 1990 Sep;52(3):243-8.
125. Benton D, et al. The influence of phosphatidylserine supplementation on mood and heart rate when faced with an acute stressor. Nutr Neurosci 2001;4(3):169-78.
126. Crook, TH. Treatment of Age-Related Cognitive Decline: Effects of Phosphatidylserine in: RM Klatz, et al. Anti-Aging Medical Therapeutics, Vol II, 1998:20-29.
127. Vannucchi MG, et al. Effect of Phosphatidylserine on Acetylcholine Release and Content in Cortical Slices From Aging Rats. Neurobiol Aging 1987, 8(5), 403-407.
128. Vannucchi, M.G., Casamenti, F., Pepeu, G. Decrease of acetylcholine release from cortical slices in aged rats: investigations into its reversal by Phosphatidylserine. J. Neurochem 1990, 55, 819-25.
129. Pepeu, G., Giovanelli, L., Giovannini, M.G., Pedata, F. Effects of Phosphatidylserine on cortical acetylcholine release and calcium uptake in adult and aging rats. In Phospholipid research and the nervous system. Biochemical and molecular pharmacology. Horrocks, L.A., Freysz, L., Toffano, G. (Eds), Liviana Press, Padova, 1986, 265-271.
130. Casamenti, F., Mantovani, P., Amaducci, L., Pepeu, G. Effect of phosphatidylserine on acetylcholine output from the cerebral cortex of the rat. J. Neurochem 1979, 32, 529-533.
131. Casamenti, F., Scali, C., Pepeu, G. Phosphatidylserine reverses the age-dependent decrease in cortical acetylcholine release: a microdialysis study, Eur. J. Pharmacol 1991, 194, 11-16.
132. Pedata, F., Giovannelli, L., Spignoli, G., Giovannini, M.G., Pepeu, G. Phosphatidylserine increases acetylcholine release from cortical slices in aged rats. Neurobiol Aging 1985, 6, 337-339.
133. Mazzari S, Battistella, A. Phosphatidylserine effects on dopamine release from striatum synaptosomes. In: Multidisciplinary Approach to Brain Development. Benedetta, C., Balazs, R., Gombos, G., Porcellani, G. (Eds.). Elsevier/North Holland, Amsterdam, 1980, 569-570.
134. Louis-Sylvestre. Phosphatidylserine and memory problems in aged subjects. Cahiers de Nutrition et de Dietetique 1999, 34:349-357.
135. Hamm, M. Ernährungswissenschaftliche Stellungnahme zur Veränderung der nutritiven Versorgung mit Phosphatidylserin (Nutritional-scientific statement on the change of nutritive provision with phosphatidylserine), 2002.
136. Calderoni, G., Aporti, F., Bellini, F., Sonetti, A.C., Rubini, R., Telato, S., Xu, C., Canotti, A., Toffano, G. Phospholipids as pharmacological tools in the aging brain. In: Horrocks, L.A., Kanfer, J.N., Porcellati, G. (Eds). Phospholipids in the nervous system,Vol II, Physiological roles. Raven Press, New York, 1985, 11-19.
137. Kaibuchi K, et al. Cooperative roles of various membrane phospholipids in the activation of calcium-activated, phospholipid-dependent protein kinase. J. Biol. Chem. 1981, 256, 7146-7149.
138. Raese, J., Patrick, R.L., Barchas, J.D. Phospholipid-induced activation of tyrosine hydroxylase from rat brain striatal synaptosomes. Biochem Pharmacol 1976, 25, 2245-2250.
139. Gindin J, Novikov M, Dedar D, Walter-Ginzburg A, Naor S, Levi S: The Effect of soy plant phosphatidylserine of age-associated memory impairment and mood in the functioning elderly. The Geriatric Institute for Education and Research, and Department of Geriatrics, Kaplan Hospital, Rehovot, Israel 1995.
140. Suzuki, S., Yamatoya, H., Sakai, M., Kataoka, A., Furushiro, M., Kudo, S. Oral Administration of Soybean Lecithin Transphosphatidylated Phosphatidylserine Improves Memory Impairment in Aged Rats. J. Nutr. 2001, 131, 2951-2956.
141. Blokland, A., Honig, W., Brouns, F., Jolles, J. Cognition-enhancing properties of subchronic phosphatidylserine (PS) treatment in middle-aged rats: comparison of bovine cortex with egg PS and soybean PS. Nutrition 1999, 15, 778-783.
142. Fritz, B. Phosphatidylserine: Have we found a Medically Proven Cortisol Antagonist at Last? IM February 1996, 74-75.
143. Fritz, B. Phosphatidylserine: Can this natural supplement reduce cortisol elevation from workouts? Muscle & Fitness,October 1996, 98-100.
144. Razavi SM, et al. Red Grape Seed Extract Improves Lipid Profiles and Decreases Oxidized Low-Density Lipoprotein in Patients with Mild Hyperlipidemia. J Med Food 16 (3) 2013, 255–258.
145. Devaraj S, et al. Supplementation with a pine bark extract rich in polyphenols increases plasma antioxidant capacity and alters the plasma lipoprotein profile. Lipids 2002;(37):931-934.
146. Reimann HJ, et al. Histamine and acute hemorrhagic lesions in rat gastric mucosa: Prevention of stress ulcer by catechin. Agents Actions 7(1):6972, 1977.
148. Waagepetersen HS, et al. The GABA paradox: multiple roles as metabolite, neurotransmitter, and neurodifferentiative agent. J Neurochem, 73:1335–42, 1999.
149. Goddard, A.W., Mason, G.F., Almai, A., Rothman, D.L., Behar, K.L., Petroff, O.A.C., Charney, D.S., Krystal, J.H. Reductions in occipital cortex gaba levels in panic disorder detected with h-magnetic resonance spectroscopy. Arch Gen Psychiatry, 58:556-561, 2001.
150. Cavagnini, F., et al. Effect of acute and repeated administration of gamma aminobutyric acid (GABA) on growth hormone and prolactin secretion in man. Acta Endocrinol, 93:149–54, 1980.
151. Bhagavan, H.N., et al. The effect of pyridoxine hydrochloride on blood serotonin and pyridoxal phosphate contents in hyperactive children. Pediatrics, 1975;55: 437-41.
152. ___. Along with riboflavin, vitamin B-6 deficiency has a primary role in the cause of emotional disorder. British Journal of Psychiatry, 141(1982):271-272.
153. ___. Current data suggest that as many as 20 percent of medically cleared population of outpatient depressives may suffer from a vitamin B-6 deficit. The authors point out that nutrition, diet and vitamin levels have received very little attention in the psychiatric literature. Biological Psychiatry, 9:4 (1984):613-6.
154. ___. Does depressive illness cause vitamin B-6 inadequacy, or vice-versa? Nut Rep Int, 27 (Apr. 1993):867-873.
155. Martineau, J., et al. Vit. B6, magnesium, and combined B6-Mg: therapeutic effects. Bio Psy, 20:467-78, 1985.
156. Dolphin, et al. (eds). Vitamin B6: pyridoxal phosphate. John Wiley & Sons, 1986, chapt. 17.
157. ___. Inadequate intake of vitamins, particularly B-1, can result in mental illness. Clin. Neuro, 8 (Jul.--Sep. 1985):286-293.
158. ___. Carpal tunnel syndrome treated with riboflavin and pyridoxine. Proceedings of the Nat. Acad. of Sc. 81 (Nov. 1984):7076-8.
159. Bekaroglu M, et al. Relationships between serum free fatty acids and zinc, and attention deficit disorder: a research note. J. Child Psychol. Psychiatry 1996 Fed; 37 (2):225-7.
160. Koenig, W., et al. C-Reactive Protein, a Sensitive Marker of Inflammation, Predicts Future Risk of Coronary Heart Disease in Initially Healthy Middle-Aged Men. Circulation. 1999;99:237-242.
161. Bisoendial, R.J., et al. C-reactive protein is a mediator of cardiovascular disease. Eur Heart J (2010) 31 (17): 2087-2091.
162. Du Y, et al. Grape Seed Polyphenols Protect Cardiac Cells from Apoptosis via Induction of Endogenous Antioxidant Enzymes. J. Agric. Food Chem., 2007, 55 (5), pp 1695–1701.
163. Kiechl S., et al. Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation. 2001 Feb 27;103(8):1064-70.
164. Meir J., et al. Vitamin E Consumption and the Risk of Coronary Disease in Women. N Engl J Med 1993; 328:1444-1449.
165. Goodman DS. Vitamin A and retinoids in health and disease. N Engl J Med 1984; 310:1023-1031
166. Crook TH, et al. Effects of phosphatidylserine in age-associated memory impairment. Neurology 1991; 41(5):644-9.
167. Kim HY, et al. Inhibition of neuronal apoptosis by docosahexaenoic acid (22:6n-3). Role of phosphatidylserine inantiapoptotic effect. J Biol Chem 2000; 275(45):35215-23.
168. Schreiber S, et al. An open trial of plant-source derived phosphatidylserine for treatment of age-related cognitive decline. Isr J Psychiatry Relat Sci. 2000;37(4):302-7.
169. Garcia MC, et al. Effect of docosahexaenoic acid on the synthesis of phosphatidylserine in rat brain microsomes and C6 glioma cells. J Neurochem 1998; 70:24-30.
170. Zile MH, et al. The function of vitamin A: current concepts: (1) cell growth and differentiation, (2) reproduction, and (3) vision. Proceedings of the Society of Experimental Biology and Medicine, 172(1983):139-152.
171. Crean C, et al. "Intrastrand G-U cross-links generated by the oxidation of guanine in 5′-d(GCU) and 5′-r(GCU)". Free Radical Biology and Medicine, 2008; 45 (8): 1125–34.
172. Pageon H, et al. An in Vitro Approach to the Chronological Aging of Skin by Glycation of the Collagen: The Biological Effect of Glycation on the Reconstructed Skin Model" Annals of the New York Academy of Sciences 2005;1043(1) 529-32.
173. Soleas GJ, et al. Wine as a biological fluid: history, production, and role in disease prevention. Journal of Clinical Laboratory Analysis 1997; 11:287-313.
174. Frankel EN, et al. Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wine. Lancet 1993;341:454-457.
175. Tebib K, et al. Dietary grape seed tannins affect lipoproteins, lipoproteinlipases, and tissue lipids in rats fed hypercholesterolemic diets. J Nutr 1994;124:2451-2457.
176. Royer RJ, et al. Evaluation of venotropic drugs by venous gas plethysmography. A study of procyanidolic oligomers. (in French) Sem Hop 1981;57:2009-2013.
177. Vauzour D, et al. Polyphenols and Human Health: Prevention of Disease and Mechanisms of Action. Nutrients. 2010 Nov; 2(11): 1106–1131.
178. Buckingham V, et al. Dictionary of Flavonoids with CD-ROM. CRC Press, Taylor & Francis Group, Boca Raton, FL; 978-1466554344, 2015.
179. Seewald, E. The quantification of oligomeric proanthocyanidins in the inner and outer barks of selected b.c. conifers: a thesis submitted in partial fulfillment of the requirements for the degree of masters of science. Univ of British Columbia, 1998.
180. Surangi H, et al. Flavonoid Bioavailability and Attempts for Bioavailability Enhancement. Nutrients. 2013 Sep; 5(9): 3367–3387.
181. Murray M, et al. Procyanidolic oligomers. The Textbook of Natural Medicine. 2nd ed. London: Churchill Livingston; 1999:899-902.
182. Visser J, et al. The stabilizing effect of an oligomeric proanthocyanidin on red blood cell membrane structure of poorly controlled Type II diabetes. Nutrition & Diabetes (2017) 7, e275; doi:10.1038/nutd.2017.25
183. Sivonova M, et al. The effect of Pycnogenol on the erythrocyte membrane fluidity. Gen Physiol Biophys 2004; 23: 39–51
184. Ohnishi ST, et al. Sickle cell anemia: a potential nutritional approach for a molecular disease. Nutrition 2000; 16: 330–338
185. Schafer A, et al. Inhibition of COX-1 and COX-2 activity by plasma of human volunteers after ingestion of French maritime pine bark extract. Biomed Pharmacother 2006; 60: 5–9.
186. Cho KJ, et al. Inhibition mechanisms of bioflavonoids extracted from the bark of Pinus maritima on the expression of proinflammatory cytokines. Ann N Y Acad Sci 2001; 928: 141–156.
187. Cheda VS, et al. Antioxidant/prooxidant activity of a polyphenolic grape seed extract. Food Chem 2010;121(1):132-9.
188. Quideau S. Why bother with polyphenols? Groupe Polyphenols. Institut Européen de Chimie et Biologie, Centre de Recherche en Chimie Moléculaire, Laboratoire de Chimie Organique et Organométallique (UMR CNRS 5802), Université Bordeaux 1; 2011.
189. Mennen L, et al. Risks and safety of polyphenol consumption. Am J Clin Nutr. 2005 Jan;81(1 Suppl):326S-329S.
190. Baxter, NJ, et al. Multiple interactions between polyphenols and a salivary proline-rich protein repeat result in complexation and precipitation. Biochemistry. 1997 May 6;36(18):5566-77.
191. Martin KR, et al. Polyphenols as dietary supplements: a double-edge sword. Nutr Diet Suppl. 2009;2:1-12.
192. Trugo LC, et al. Lupin: Tannins, Encyclopedia of Food Sciences and Nutrition 2nd ed. Academic Press; 2003;
193. Aldred EM, Phenols, Pharmacology: A Handbook for Complementary Healthcare Professionals. Elsevier's Health Sciences. Philadelphia PA; 2009. ISBN: 978-0-443-06898-0.
194. Smith, MT, et al. "Beware of plant supplements called flavonoids; they could make you sick, warn UC Berkeley public health experts." 19 Sep 2000; Free Radical Bio. & Med.
195. Fukuoka T, et al. "Synthesis of Ultrahigh Molecular Weight Polyphenols by Oxidative Coupling". Macromolecules. 36 (22): 8213–5. Bibcode:2003MaMol..36.8213F.
196. Pizzi A, et al. "Low formaldehyde emission, fast pressing, pine and pecan tannin adhesives for exterior particleboard". Holz als Roh- und Werkstoff. 1994;52(5):311–5.
197. Yamashita D, et al. Delayed production of free radicals following noise exposure. Brain Research 2004;1019(1-2), 201-209.
198.Samson J, et al. Effect of noise stress on free radical scavenging enzymes in brain. Environmental toxicology and pharmacology. 10.1016/j.etap.2004.12.059.
199. Gray SL, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015 Mar;175(3):401-7.
200. Werbach MR, et al. Botanical influences on illness: A sourcebook of clinical research, Third Line Press, CA, 1994.
201. Schultz V, et al. Rational Phytotherapy: a physician's guide to herbal medicine, 4th ed. Berlin, 2001.
202. Packer L, et al. Antioxidant Food Supplements in Human Health, Academic Press, CA, 1999.
203. Lincoln J, et al. Nitric Oxide in Health and Disease, Cambridge University Press, UK, 1997.
204. Moncada S, et al. Nitric Oxide and the Cell: proliferation, differentiation and death, Princeton University Press, NJ, 1998.
205. Amsellem, et al. Endotelon dans le traitement des troubles veino-lymphatiques dy syndrome premenstrual. Etude multicentrique sur 165 patientes. (Endotelon in the treatment of venolymphatic problems in premenstrual syndrome, a multicentered study on 165 patients.) Tempo Medical November:282, 1987.
206. Ikemoto A, Kobayashi T, Watanabe S, Okuyama H. Neurite outgrowth induced by NGF is enhanced by added DHA, but suppressed by added AA. Neurochem Res 1997; 22:671-678.
207. Ikemoto A, Okuyama H. Phosphatidyl serine is actively recycled only in cells undergoing NGF-induced neuritogenesis. Neurochem Res 2000; 25:293-301.
208. Souci SW, Fachmann E, Kraut H. Food Composition and Nutrition Tables. Medpharm Scientific Pub. Stuttgart, 2014.
209. Crook, TH, et al. The Memory Cure: the safe, scientifically proven breakthrough that can slow, halt, or even reverse age-related memory loss, Simon & Schuster, NY 1998.
210. Talbott, S. The cortisol connection: why stress makes you fat and ruins your health, Hunter House Pub., CA 2002.
211. Kidd, PM. PS (PhosphatidylSerine): Nature's Brain Booster: a vital lipid nutrient for memory, mood and stress, Total Health Communications, 2005.
212. Kidd, PM. The phospholipids as anti-aging nutraceuticals. In, Anti-Aging Medical Therapeutics, Vol IV, ed. Klatz RM and Goldman R. Chicago, IL: American Academy of Anti-Aging Medicine; 282-95, 2000.
213. Richter Y, et al. The effect of soybean-derived phosphatidylserine on cognitive performance in elderly with subjective memory complaints: a pilot study. Clin Interv Aging 2013, 8:557-63.
214. Youngjohn JR, Larrabee GJ, Crook TH. First-last names and the grocery list selective reminding test: two computerized measures of everyday veral learning. Archives of Clinical Neuropsychology 6:287-300, 1991.
215. Jager R, Purpura M, Geiss KR, Weib M, Baumeister J, Amatulli F, Schroder L, Herwegen H. The effect of phosphatidylserine on golf performance. Journal of the International Society of Sports Nutrition 2007, 4:23 doi:10.1186/1550-2783-4-23.
216. Starks MA, et al. The effects of phosphatidylserine on endocrine response to moderate intensity exercise. J Int Soc Sports Nutr. 2008, 5:11.
217. Hirayama S, et al. The effect of phosphatidylserine administration on memory and symptoms of attention-deficit hyperactivity disorder (ADHD) - a randomized, double-blind, placebo-controlled clinical trial. J Hum Nutr Diet 2014, Suppl 2:284-91
218. Hirayama H, et al. Effect of phosphatidylserine administration on symptoms of attention-deficit/hyperactivity disorder in children. Agro Food Ind. Hi Tech 2006;17:32–36.
219. Delwaide PJ, Gyselynck-Mambourg AM, Hurlet A, Ylieff M. Double-blind randomized controlled study of phosphatidylserine in senile demented patients. Acta Neurol Scand. 1986 Feb;73(2):136-40.
220. Palmieri G, Palmieri R, Inzoli MR, et al. Double-blind controlled trial of phosphatidylserine in patients with senile mental deterioration. Clin Trials J . 1987;24:73-83.
221. Ransmayr G, Ploerer S, Gerstenbrand F, Bauer G. Double-blind, placebo-controlled trial of phosphatidylserine in patients with arteriosclerotic encephalopathy. Clinical Trials Journal 1987;24:62-72.
222. Amaducci L. Phosphatidylserine in the treatment of Alzheimer's disease: results of a multicenter study. Psychopharmacol Bull. 1:130-4, 1988.
223. Crook T, Petrie W, Wells C, et al. Effects of phosphatidylserine in Alzheimer's disease. Psychopharmacol Bull. 1992;28:61-66.
224. Nerozzi D, Aceti F, Melia E, et al. Phosphatidylserine and memory disorders in the aged [English abstract]. Clin Ther. 120:399-404, 1987.
225. Villardita C, Grioli S, Salmeri G, et al. Multicentre clinical trial of brain phosphatidylserine in elderly patients with intellectual deterioration. Clin Trials J. 1987;24:84-93.
226. Furushiro M, Suzuki S, et al. Effects of oral administration of soybean lecithin transphosphatidylated phosphatidylserine PS on impaired learning of passive avoidance in mice. Jpn. J. Phamacol. 1997;75:447-450.
227. Sakai M, Yamatoya H, Kudo S. Pharmacological effects of phosphatidylserine synthesized from soybean lecithin on brain functions in rodents. Nutr.Sci.Vitaminol. 1996;42:47-54.
228. Burke R. Phosphatidylserine protects from muscle damage. Nutrition Science News, 2000, 5, 371-372.
229. Masquelier, J. "Les procyanidols du vin leur role dans l'alcolisme." pp. 88-93.
230. Bombardelli, E. Vitis vinifera L. Fitoterapia 1995;66:291-317.
231. Sano M, et al. A controlled trial of selegiline, alpha-tocopherol or both as treatment for alzheimer's disease. N. Engl. J. Med. 1997 Apr:1216-1222.
232. Black P. Psychoneuroimmunology. Brain and immunity. Scientific American 1995 Nov-Dec: 16-25.
233. Fabris N, et al. Neuroimmunomodulations: the state of the art. Ann NY Acad Sci 1994; Vol 741.
234. Jankovic BD, et al. Neuroimmune interactions. Ann NY Acad Sci 1987; Vol 496.
235. Snyder S. Nitric oxide: first in a new class of neurotransmitter. Science 1992 Jul; Vol 253.
236. Streight WJ, et al. The brain's immune system. Sci American 1995 Nov; 273(5):54-56.
237. Koller-Stametz J, et al. Role of nitric oxide in exercise-induced vasodilation in man. Life Sci 62: 1035-1043, 1998
238. Koss MC. Functional role of nitric oxide in regulation of ocular blood flow. Eur J Pharmacol 374: 161-174, 1999.
239. Dorner GT, et al. Nitric oxide regulates retinal vascular tone in man. Am J Physiol Heart Circ Physiol (May 15, 2003). 10.1152/ajpheart.00111.2003.
240. Beal MF. Aging, energy and oxidative stress in neurodegenerative diseases. Ann Neurol 1995 Sept; 38(3):357-68.
241. Palmer AM, et al. Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease. Brain Res 1994; 645:338-47.
242. Steinman L. Autoimmune disease. Sci Amer 1993 Sept;107-14.
243. Fletcher AE. Free radicals, antioxidants and eye diseases: evidence from epidemiological studies on cataract and age-related macular degeneration. Ophthalmic Res. 2010;44(3):191-8.
244. Fletcher AE, et al. Sunlight exposure, antioxidants, and age-related macular degeneration. Arch Ophthalmol. 2008 Oct;126(10):1396-403. doi: 10.1001/archopht.126.10.1396.
245. Lubica H. Flavonoids in prevention of diseases with respect to modulation of Ca-pump function. Interdiscip Toxicol. 2011 Sep; 4(3): 114–124.
246. Bohn T. Dietary factors affecting polyphenol bioavailability. Nutrition Reviews 2014;72(7):429–452.
247. Chasen Paul J, et al. Methods and compositions for treating attention-deficit/hyperactivity disorder. "A regimen and composition for treating attention deficit/disorder (ADHD) by the use of proanthocyanidin both with and without a heterocyclic anti-depressant, preferably desipramine and a citrus bioflavinoid." U.S. Patent No. 5,719,178, 1998.
248. Stamatovic SM, et al. Brain endothelial cell-cell junctions: how to "open" the blood brain barrier. Curr Neuropharmacol. Sep; 6(3): 179–192, 2008.
249. Saracco and Estachy, oral applications of extracts of proanthocyanidins slow down the progression of the retinopathy disease. Gaz. Med. France, 88: 2035 2038, 1981.
250. Fromantin M. Les Oligomeres Procyanidoliques dans le traitement de la fragilite capillaire et de la Retinopathie chez les diabetiques. Med Int. 16(11), 432-434, 1981.
251. Gabor et al. action of proanthocyanidins in case of diabetic retinopathy as being due to sealing of leaky capillaries. Phlebologie, 22; 178-182, 1993.
252. Kumpulainen JT, et al. Natural Antioxidants and Anticarcinogens in Nutrition, Health and Disease Elsevier: 1999.
253. Rice-Evans CA, et al. Free Rad. Biol. Med. 20:933, 1996.
254. Salah N, et al. Arch. Biochem. Biophys. 322:339, 1995.
255. Buening MK, et al. A.H. Canc. Res. 41:67, 1981.
256. Kolodziej, H, et al. Phytother. Res. 9:410, 1995.
257. Kingsley M, et al. Effects of phosphatidylserine supplementation on exercising humans. Sports Med (2006) 36:657-669.
258. Kingsley MI, Miller M, Kilduff LP, McEneny J, Benton D: Effects of phosphatidylserine on exercise capacity during cycling in active males: Med Sci Sports Exerc 2006, 38(1):64-71.
259. Kingsley MI, Wadsworth D, Kilduff LP, McEneny J, Benton D: Effects of phosphatidylserine on oxidative stress following intermittent running: Med Sci Sports Exerc 2005, 37(8):1300-1306.
260. Bouhamidi R, et al. High protection by grape seed proanthocyanidins (GSPC) of polyunsaturated fatty acids against UV-C induced peroxidation. C R Acad Sci III 321:31-8, 1998.
261. Virgili F, et al. Procyanidins extracted from pine bark protect alphatocopherol in ECV 304 endothelial cells challenged by activated RAW 264.7 macrophages: role of nitric oxide and peroxynitrite. FEBS Lett 1998;431:315-318.
262. Moriconi S, et al. Clinical study on activity of vitis vinifera procyanidolic oligomers on myopic patients retinic sensitivity. Ann Ottal Clin Ocul 114:585-94, 1988.
263. Fusi L, et al. Procyanidolic oligomers effects in patients working at a display unit. Ann Ottal Clin Ocul 116:575-84, 1990.
264. Putter M, et al. Inhibition of smoking-induced platelet aggregation by aspirin and pycnogenol. Thromb Res 95:155-61, 1999
265. Fitzpatrick DF, et al. Endothelium-dependent vascular effects of procyanidins. J Cardiovasc Pharmacol 32:509-15, 1998.
266. Drubaix I, et al. Synthesis of glycoconjugates by human diseased veins: modulation by procyanidolic oligomers. Intl J Experiment Pathol 78:117-21, 1997.
267. Gavignet C, et al. Study of the influence of procyanidolic oligomers on cultured mesenchymal cells. I - Effect on the attachment, the proliferation and detachment of cells. Path Biol 37:746-53, 1989.
268. Robert L, et al. Action of procyanidolic oligomers on vascular permeability. A study by quantitative morphology.Path Biol:6, 1990.
269. Doutremepuich J, et al. Effect of Endotelon (procyanidolic oligomers) on experimental acute lymphedema of the rat hindlimb. Lymphology 24:135-9, 1991.
270. Mollman H, et al. A naturally occurring bioflavonoid complex with capillary protective action. Therapiewoche 33:4967, 1983.
271. Bagchi D, et al. Oxygen free radical scavenging abilities of vitamins C and E, and a grape seed proanthocyanidin extract in vitro. Res Commun Mol Pathol Pharmacol 1997;95:179-189.
272. Bagchi D, et al. Protective effects of grape seed proanthocyanidins and selected antioxidants against TPA-induced hepatic and brain lipid peroxidation and DNA fragmentation, and peritoneal macrophage activation in mice. Gen Pharmacol 30:771-6, 1998.
273. Facino RM, et al. Free radicals scavenging action and antienzyme activities of procyanidines from Vitis vinifera. A mechanism for their capillary protective action. Arzneimittelforschung 44:592-601, 1994.
274. Facino RM, et al. Sparing effect of procyanidins from Vitis vinifera on vitamin E: in vitro studies. Planta Med 64:343-347, 1998.
275. Facino RM, et al. Procyanidines from Vitis vinifera seeds protect rabbit heart from ischemia/reperfusion injury: antioxidant intervention and/or iron and copper sequestering ability. Planta Med 62:495-502, 1996.
276. Simonetti P, et al. Procyanidins from Vitis vinifera seeds: in vivo effects on oxidative stress. J Agric Food Chem 50:6217-6221, 2002.
277. Preuss HG, et al. Effects of niacin-bound chromium and grape seed proanthocyanidin extract on the lipid profile of hypercholesterolemic subjects: a pilot study. J Med 31:227-246, 2000.
278. Bayeta E, et al. procyanidins inhibits generation of inflammatory mediators in macrophages. Nutr Res 20:249-259, 2000.
279. Blazso G, et al. Antiinflammatory activities of procyanidin-containing extracts from Pinus pinaster Ait. after oral and cutaneous application. Pharmazie 1997;52:380-382.
280. Li WG, et al. Antiinflammatory effect and mechanism of proanthocyanidins from grape seeds. Acta Pharmacol Sin 22:1117-1120, 2001.
281. Liviero L, et al. Antimutagenic activity of procyanidins from Vitis vinifera. Fitoterapia 65:203-209, 1994.
282. Noda Y, et al. Hydroxyl and superoxide anion radical scavenging activities of natural source antioxidants using the computerized JES-FR30 ESR spectrometer system. Biochem Mol Biol Int 1997;42:35-44.
283. Sato M, et al. Cardioprotection with alcohol: role of both alcohol and polyphenolic antioxidants. Ann N Y Acad Sci 957:122-135, 2002.
284. Natella F, et al. Grape seed proanthocyanidins prevent plasma postprandial oxidative stress in humans. J Agric Food Chem 50:7720-7725, 2002.
285. Hosseini S, et al. procyanidins in the management of asthma. J Med Food 4:201-209, 2001.
286. Putter M, et al. Inhibition of smoking-induced platelet aggregation by aspirin and procyanidins. Thromb Res 95:155-161, 1999.
287. Yamakoshi J, et al. Safety evaluation of proanthocyanidin-rich extract from grape seeds. Food Chem Toxicol 40:599-607, 2002.
288. Chang WC, et al. Inhibition of platelet aggregation and arachidonate metabolism in platelets by procyanidins. Prostaglandins Leukot Essent Fatty Acids 38:181-188, 1989.
289. Cohen, SA, et al. Age-related alterations of NMDA-receptor properties in the mouse forebrain: partial restoration by chronic phosphatidylserine treatment. Brain Research 1992, 584, 174-180.
290. Nair MP, et al. Grape seed extract proanthocyanidins downregulate HIV-1 entry coreceptors, CCR2b, CCR3, and CCR5 gene expression by normal peripheral blood mononuclear cells. Biol Res 35:421-431, 2002.
291. Pepeu G, et al. A review of phosphatidylserine pharmacological and clinical effects. Is phosphatidylserine a drug for the ageing brain? Pharmacol Res. 1996;33:73-80.
292. Packer L, et al. Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (Pinus maritima) bark, procyanidins. Free Radic Biol Med 27:704-24, 1999.
293. Weingest K, et al. Procyanidine aus Früchten Zur Kenntnis der Proanthocyanidine. Liebigs A Chem 711, 184-204, 1968.
294. Facino RM, et al. Diet enriched with procyanidins enhances antioxidant activity and reduces myocardial post-ischaemic damage in rats. Life Sci 64:627-42, 1999.
295. Hertog MG, et al. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 342:1007-11, 1993.
296. Constant J. Alcohol, ischemic heart disease, and the French paradox. Coronary Artery Disease 8:645-9, 1997.
297. Gabor MR. Vascular effects of oxygen-derived free radicals. Biology & Med 4:107-120, 1988.
298. Cheshier JE, et al. Immunomodulation by pycnogenol in retrovirus-infected or ethanol-fed mice. Life Sci 58:87-96, 1996.
299. Bagchi M, et al. Smokeless tobacco, oxidative stress, apoptosis, and antioxidants in human oral keratinocytes. Free Radic Biol Med 26:992-1000, 1999.
300. Nelson A, et al. Pycnogenol inhibits macrophage oxidative burst, lipoprotein oxidation, and hydroxyl radical induced DNA damage. Drug Devel Industr Pharm 1998;24:139-44.
301. Virgili F, et al. Procyanidins extracted from Pinus maritima: scavengers of free radical species and modulators of nitrogen monoxide metabolism in activated murine RAW 264.7 macrophages. Free Radical Biology & Medicine 1998;24:1120-9.
302. Fitzpatrick DF, et al. Isolation and characterization of endothelium dependent vasorelaxing compounds from grape seeds. J Agric Food Chem 48:6384-6390, 2000.
303. Saito M, et al. Antiulcer activity of grape seed extract and procyanidins. J Agricult Food Chem 46:1460-64, 1998.
304. S Iravani1, et al. Pharmaceutical and nutraceutical effects of Pinus pinaster bark extract. Res Pharm Sci. Jan-Jun; 6(1): 1–11, 2011.
305. Cho KJ, et al. Effect of proanthocyanidins extracted from the bark of Pinus maritime on proinflammatory cytokine interleukin-1 production in lipopolysaccharide-stimulated RAW 264.7. Toxicol Appl Pharmacol. 168:64–71, 2000.
306. Park YC, et al. Activity of monomeric, dimeric, and trimeric flavanols on NO production, TNFalpha secretion, and NF-kappaB-dependent gene expression in RAW 264.7 macrophages. FEBS Lett. 465:93–97, 2004.
307. Banerjee B, et al. Beneficial effects of a novel IH636 grape seed proanthocyanidin extract in the treatment of chronic pancreatitis. Digestion 63:203-206, 2001.
308. Liu FJ, et al. Proanthocyanidins enhances immune and haemopoietic functions in senescence-accelerated mice. Cell Mol Life Sci 54:1168-72, 1998.
309. Bagchi D, et al. Protection against drug- and chemical-induced multi-organ toxicity by a novel grape seed proanthocyanidin extract. Drugs Exp Clin Res 27:3-15, 2001.
310. Ray SD, et al. In vivo protection of DNA damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity, and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract. Res Commun Mol Pathol Pharmacol 107:137-166, 2000.
311. Stefanovic V, et al. Reversal of experimental myoglobinuric acute renal failure with bioflavonoids from seeds of grape. Ren Fail 22:255-266, 2000.
312. Witte MB, et al. Enhancement of fibroblast collagen synthesis by nitric oxide. Nitric Oxide 4:572-582, 2000.
313. Stallmeyer B, et al. The function of nitric oxide in wound repair: inhibition of inducible nitric oxide-synthase severely inhibits wound reepithelialization. J Invest Dermatol 113:1090-1098, 1999.
314. Frank S, et al. Nitric oxide triggers enhanced induction of vascular endothelial growth factor expression in cultured keratinocytes (HaCaT) and during cutaneous wound repair. FASEB J 13:2002-2014, 1999.
315. Most D, et al. Characterization of incisional wound healing in inducible nitric oxide synthase knockout mice. Surgery 132:866-876, 2002.
316. Khanna S, et al. Upregulation of oxidant-induced VEGF expression in cultured keratinocytes by a grape seed proanthocyanidin extract. Free Radic Biol Med 31:38-42, 2001.
317. Khanna S, et al. Dermal wound healing properties of redox-active grape seed proanthocyanidins. Free Radic Biol Med 33:1089-1096, 2002.
318. Howard J. "Americans devote more than 10 hours a day to screen time, and growing," CNN updated Jul 29, 2016; reporting on Nielsen company audience report Q1 2016 dated Jun 27, 2016.
319. Beatty S, et al. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 45(2)115–134, 2000.
320. Dillon J, et al. Transmission of light to the aging human retina: possible implications for age related macular degeneration. Exp Eye Res. 79(6)753–759, 2004.
321. Algvere PV, et al. Age-related maculopathy and the impact of blue light hazard. Acta Ophthalmol Scand. 84(1)4–15, 2006.
322. "Blue light has a dark side. Exposure to blue light at night, emitted by electronics and energy-efficient light bulbs, harmful to your health." Harvard Health Letter, Harvard Health Pub., Harvard Med School. May 2012, updated Sep 2, 2015.
324. Rose RC, et al. Ocular oxidants and antioxidant protection. Proc Soc Exp Biol Med 217(4):397-407, 1998.
325. Van der Hagen AM, et al. Free radicals and antioxidant supplementation: a review of their roles in age related macular degeneration. J Am Optom Assoc 1993;64:871-78.
326. Zastrow L, et al. UV, visible and infrared light. Which wavelengths produce oxidative stress in human skin? Hautarzt. 2009 Apr;60(4):310-7.
327. Shaw PX, et al. Oxidative stress, innate immunity, and age-related macular degeneration. AIMS Mol Sci. 2016;3(2):196–221.
328. Yang H, et al. Protective effect of grape seed extract against oxidative stress-induced cell death in a staurosporine-differentiated retinal ganglion cell line. Curr Eye Res. 2012;37:339–344.
329. Wang H, et al. Oligomeric proanthocyanidin protects retinal ganglion cells against oxidative stress-induced apoptosis. Neural Regen Res. 2013 Sep 5; 8(25): 2317–2326.
330. Zeisel SH. Choline: an essential nutrient for humans. Nutrition. 2000 Jul-Aug;16(7-8):669-71.
331. Blum K, et al. Attention-deficit-hyperactivity disorder and reward deficiency syndrome. Neuropsychiatr Dis Treat. 2008 Oct;4(5):893-918.
332. Kapur S, et al. Role of the dopaminergic system in depression. Biol Psychiatry. 1992 Jul 1;32(1):1-17.
333. Hochreiter-Hufford AE, et al. Phosphatidylserine receptor BAI1 and apoptotic cells as new promoters of myoblast fusion. Nature. 2013;497:263-267
334. Joy JM, et al. Phosphatidic acid enhances mTOR signaling and resistance exercise induced hypertrophy. Nutrition & metabolism. 2014;11:29.
335. Kato-Kataoka A, et al. Soybean-derived phosphatidylserine improves memory function of the elderly Japanese subjects with memory complaints. J Clin Biochem Nutr. 2010;47:246-255.
336. Svennerholm L. Distribution and fatty acid composition of phosphoglycerides in normal human brain. J Lipid Res. 1968;9:570-579
337. Mozzi R, et al. Metabolism and functions of phosphatidylserine in mammalian brain. Neurochem Res. 2003;28:195-214.
338. Yong T, et al. Research on human memory enhancement by phosphatidylserine. Chongqing Medicine. 2011;40:3022-3023.
339. Roher AE, et al. Cerebral blood flow in Alzheimer's disease. Vascular Health and Risk Management 2012;8:599–611.
340. Meunier MT, et al. Activité Antiradicalaire d'Oligomères Procyanidolique et d'Anthocyanosides vis-à-vis de l'Anion Superoxyde et vis-à-vis de la Lipoperoxydation. Plantes médicinales et phytothérapie. 1989;23(4):267-274.
341. Barbier A, Maffrand JP, Savi P, Unkovic J, Vilain P. International Congress on Angiology in Toulouse, France. 1988:1-40.
342. Bos M-A, Vennat B, Meunier M-T, Pouget M-P, Pourrat A, Fialip J. Procyanidins from Tormentil: Antioxident Properties towards Lipoperoxidation and Anti-Elastase Activity Biol. Pharm. Bull. 1996;19(1):146-148.
343. de Haan B, et al. Protection of Vascular Endothelial Cells From Oxidative Damage by Oligomeric Proanthocyanidins. XVI Congress of the Oxygen Club of California on Oxidants and Antioxidants in Biology. 2006;3/15-18, Santa Barbara, California.
344. de Haan B, et al. Oligomeric Proanthocyanidins Protect Vascular Endothelial Cells from Lipid Oxidation. 14th Inflammation Research Association Meeting. 2006;10/15-19. Cambridge, Maryland.
345. de Haan B, Achanta G, van der Vlies D, Post JA. Oligomeric Proanthocyanidins effectively inhibit LDL oxidation: A Mechanistic study using a lipophilic, Oxidation-sensitive, Fluorescent Probe. 14th Annual SFRBM Meeting, 2007:11/14-18, Washington DC.
346. Hogg N, et al. Nitric oxide and lipid peroxidation. Biochim Biophys Acta 1411: 378–384, 1999.
347. Cutler RG. Aging and Oxygen Radicals. In Physiology and Oxygen Radicals, Clinical Monograph Series. Bethseda, Md.: American Physiology Society; 1986:251-285.
348. Cutler RG. Human longevity and aging: possible role of reactive oxygen species. Annals of the NY Academy of Sciences, 1991;621:1-28.
349. Floyd R. Role of oxygen free radicals in carcinogenesis and brain ischemia. Federation of American Societies for Experimental Biology Journal 1990;4:2587-2597.
350. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. New England Journal of Medicine, 1985;312(3)159-163.
351. Proctor PH, et al. Free radicals and disease in man. Physiological Chemistry and Physics, 1984;16:175.
352. Histamine in the nervous system. Physiol Rev. 2008 Jul;88(3):1183-241
353. Haas HL, Sergeeva OA, Selbach O. Nuutinen S, Panula P. Histamine in neurotransmission and brain diseases. Adv Exp Med Biol. 2010;709:95-107.
354. Mannaioni PF, et al. The release of histamine by free radicals. Free Radical Biology and Medicine, 1988;5(3)177-197.
355. Rahman K. Studies on free radicals, antioxidants, and co-factors. Clin Interv Aging. 2007 Jun; 2(2): 219–236.
356. Harman D. Ageing: a theory based on free radical and radiation chemistry. J Gerontol. 1956;2:298–300.
357. Blazso G, et al. Anti-inflammatory and super oxide radical scavenging abilities of procyanidins containing extract from the bark of pinus pinaster sol. and its fractions. Pharm Pharmacol Lett 1994;3,217-220.
358. Blazso G, et al. ACE inhibition and hypotensive effect of a procyanidins containing extract from the bark of pinus pinaster sol. Pharm Pharmacol Lett 1996;6-8-11.
359. Ueda T, et al. Preventitive effects of natural and synthetic antioxidants on lipid peroxidation in the mammalian eye. Ophthalmol 1996;28:184-192
360. Elstner EF, et al. Radical scavenger properties of leucocyanidine. In Flavonoids in Bio and Medicine III Current Issues in Flavonoid Research. Natl Univ of Singapore Press, Singapore. 1990;N.P. Das, ed.:227-235.
361. Wei ZH, et al. Procyanidins enhances endothelial cell antioxidant defences. Redox Rep. 1997;3:147-155.
362. Rong Y, et al. Procyanidins protects vascular endothelial cells from t-butyl hydroperoxide induced oxidant injury. Biotechnol Ther. 199401995;5:117-126.
363. van Jaarsveld H, et al. Effect of flavonoids in the outcome of myocardial mitochondrial ischemia/reperfusion injury. Res Commun Mol Pathol Pharmacol. 1996;91:65-75.
364. Ursini F, et al. Microsomal lipid peroxidation: mechanism of initiation. Free Radic Biol Med. 1989;91:65-75.
365. Rice-Evans, et al. Structure-antioxidant activity relationship of flavonoids and phenolic acids. Flavonoids in Health and Disease (Rice-Evans C and Packer L, eds.) Dekker, New York. 1997;199-209.
366. El-Alfy AT, et al. Amelioration of the cardiovascular manifestations of the yellow scorpion Leiurus quinquestriatus envenomation in rats by red grape seeds proanthocyanidins. Toxicon. 2008 Mar 1;51(3):321-33.
367. Casas-Tinto S, et al. The endoplasmic reticulum (ER) stress factor XBP1s prevents amyloid-β neurotoxicity. Hum Mol Genet. 2011 Jun 1; 20(11): 2144–2160.
368. El-Alfy AT, et al. Protective effect of red grape seeds proanthocyanidins against induction of diabetes by alloxan in rats. Pharmacological Research. 2005;52:3(Sep)264-270.
369. Packer L, et al. Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (pinus maritima) bark. Free Radical Biology and Medicine. 1999;27(5-6)Sep:704-724.
370. Caballero B. Principles of Human Nutrition. Antioxidant Nutrients. Johns Hopkins Univ., Johns Hopkins Bloomberg School of Public Health. 2004;Course 222.641.81
371. Mansouri E, et al. Effects of grape seed proanthocyanidin extract on oxidative stress induced by diabetes in rat kidney. Iran Biomed J. 2011;15(3):100-6.
372. Kolacek M, et al. Effect of natural polyphenols, on superoxide dismutase and nitric oxide synthase in diabetic rats. Prague Med Rep. 2010;111(4):279-88.
373. Sun Y, et al. Grape seed proanthocyanidin extract protects the retina against early diabetic injury by activating the Nrf2 pathway. Exp Ther Med. 2016 Apr; 11(4): 1253–1258.
374. D Janigro, GA. Regulation of blood-brain barrier endothelial cells by nitric oxide. Circ Res. 1994;75:528-538.
375. Chiou GC. Review: effects of nitric oxide on eye diseases and their treatment. J Ocul Pharmacol Ther. 2001 Apr;17(2):189-98.
376. Kaprinis K, et al. Decreased hyaluronan concentration during primary rhegmatogenous retinal detachment. European Journal of Ophthalmology 2016 Nov 4;26(6):633-638.
377. Basic Neurochemistry: Molecular, Cellular and Medical Aspects. 6th ed. Siegel GJ, Agranoff BW, Albers RW, et al., editors. Philadelphia: Lippincott-Raven; 1999.
378. Volkow ND, et al. Association Between Decline in Brain Dopamine Activity With Age and Cognitive and Motor Impairment in Healthy Individuals. Amer. Journal of Psychiatry, 1998 155:3(3):344-349.
379. Francis CL, et al. The beneficial effects of fruit polyphenols on brain aging. Neurobiology of Aging 26S(2005)S128–S132.
380. Esch T, et al. Stress-related diseases—a potential role for nitric oxide. Med Sci Monit 2002;8:RA103–18.
381. Hensley K, et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem 1995;65:2146–56.
382. Hensley K, et al. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J Neurosci 1998;18:8126–32.
383. McGeer PL, et al. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 2004;10(Suppl. 1):S3–7.
384. Rogers J, et al. Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging 1996;17:681–6.
385. Deshane J, et al. Proteomics analysis of rat brain protein modulations by grape seed extract. J Agric Food Chem. 2004 Dec 29;52(26):7872-83.
386. Jackson, SP. The growing complexity of platelet aggregation. Blood 2007 109:5087-5095
387. Parvizi J, et al. COX-2 Agents in High Yield Orthopaedics. 2010;122-124. Elsevier Inc.
388. Josefson D. COX 2 inhibitors can affect the stomach lining. British Medical Journal (BMJ). 1999 Dec 11; 319(7224): 1518.
389. Wang G, et al. Role of nitric oxide in regulating secreted phospholipase A2 release from astrocytes. Neuroreport. 2005 Aug 22;16(12):1345-50
390. Woo YJ, et al. Grape seed proanthocyanidin extract ameliorates monosodium iodoacetate-induced osteoarthritis. Exp Mol Med. 2011 Oct 31; 43(10): 561–570.
391. Badimon L, et al. Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease. Eur Heart J Acute Cardiovasc Care. 2012 Apr; 1(1): 60–74.
392. Pretorius E, et al. A comprehensive review on eryptosis. Cell Physiol Biochem 2016; 39: 1977–2000.
393. Bagchi DM, et al. Free radicals and grape seed proanthocyanidin extract: importance in human health and disease prevention. Toxicology. 2000 Aug 7;148(2-3):187-97.
394. Yun SH, et al. Platelet Activation: The Mechanisms and Potential Biomarkers. Biomed Res Int. 2016; 2016: 9060143.
395. Erlejman AG, et al. TNFalpha-induced NF-kappaB activation and cell oxidant production are modulated by hexameric procyanidins in Caco-2 cells. Arch Biochem Biophys. 2008 Aug 15;476(2):186-95.
396. Tunon MJ, et al. Potential of flavonoids as anti-inflammatory agents: modulation of pro-inflammatory gene expression and signal transduction pathways. Curr Drug Metab. 2009 Mar;10(3):256-71.
397. Araghi-Nicknam M, et al. Pine bark extract reduces platelet aggregation. Int Med 1999;2:73-77.
398. Vitseva O, et al. Grape seed and skin extracts inhibit platelet function and release of reactive oxygen intermediates. J Cardiovasc Pharmacol. 2005; 46:445-51.
399. Stokes, KY, et al. Platelets: a critical link between inflammation and microvascular dysfunction. J Physiol. 2012 Mar 1; 590(Pt 5): 1023–1034.
400. Zhao Y, et al. Vascular nitric oxide: Beyond eNOS. Journal of Pharmacological Sciences 2015 Oct;129(2):83-94.
401. Dioguardi FS. To Give or Not to Give? Lessons from the Arginine Paradox. J Nutrigenet Nutrigenomics 2011;4:90–98.
402. Janle EM et al. Pharmacokinetics and tissue distribution of 14C-labeled grape polyphenols in the periphery and the central nervous system following oral administration. J Med Food 2010;13(4):926-33.
403. Wang J, et al. Grape-derived polyphenolics prevent Abeta oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease. J Neurosci. 2008;28:6388–6392.
404. Li MH, et al. Protective effects of oligomers of grape seed polyphenols against β-amyloid-induced oxidative cell death. Ann NY Acad Sci 2004;1(3):317-29.
405. Wang Y-J, et al. Consumption of grape seed extract prevents amyloid-βdeposition and attenuates inflammation in brain of an Alzheimer's disease mouse. Neurotox Res 2009;15(1):3-14.
406. Ono K, et al. Effects of grape seed-derived polyphenols on amyloid β-protein self-assembly and cytotoxicity. J Biol Chem 2008;283(47):32176-87.
407. Marzulli G, et al. Fermented grape marc: immunomodulating properties and its potential exploitation in the treatment of neurodegenerative diseases. Curr Pharm Des 2012;18(1):43-50.
408. Ho L, et al. Grape seed polyphenolic extract as a potential novel therapeutic agent in tauopathies. J Alzheimers Dis 2009;16(2):433-9.
409. Wang J, et al. Grape derived polyphenols attenuate tau neuropathology in a mouse model of Alzheimer's disease. J Alzheimers Dis 2010;22(2):653-61.
410. Wang J, et al. Potential application of grape derived polyphenols in Huntington's diesease. Translat Neurosci 2010;1(2):95-100.
411. Cady RJ, et al. Dietary grape seed polyphenols repress neuron and glia activation in trigeminal ganglion and trigeminal nucleus caudalis. Mol Pain 2010;6:91.
412. Fujishita K, et al. Grape seed extract action on astocytes reveals neuronal protection against oxidative stress via interleukin-6-mediated mechanisms. Cell Mol Neurobiol 2009;29(8):1121-9.
413. Balu M, et al. Modulatory role of grape seed extract on age-related oxidative DNA damage in central nervous system of rats. Brain Res Bull. 2006 Feb 15;68(6):469-73.
414. Chan MM, et al. Synergy between ethanol and grape polyphenols, quercetin, and resveratrol, in the inhibition of nitric oxide synthase pathway. Biocehm Pharmacol 2000;60(10):1539-48.
415. de Lange DW, et al. Polyphenolic grape extract inhibits platelet activation through PECAM-1: an explanation for the French paradox. Alcohol Clin Exp Res 2007;31(8):1308-14.
416. Jiao R, et al. Hypocholesterolemic activity of grape seed proanthocyanidins is mediated by enhancement of bile acid excretion and upregulation of CYP7A1. J Nutr Biochem 2010;21(11):1134-9.
417. Ngamukote S, et al. Cholesterol-lowering activity of the major polyphenols in grape seed. Molecules 2011;16(6):5054-61.
418. Edirisinghe I, et al. Mechanism of the endothelium-dependent relaxation evoked by a grape seed extract. Clin Sci (Lond) 2008;114(4):331-7.
419. Lekakis J, et al. Polyphenolic compounds from red grapes acutely improve endothelial function in patients with coronary heart disease. Eur J Cardiovasc Prev Rehabil 2005;12(6):596-600.
420. Mendes A, et al. Vasorelaxant effects of grape polyphenols in rat isolated aorta. Possible involvement of a purinergeic pathway. Fundam Clin Pharmacol 2003;17(6):673-81.
421. Felice F, et al. Red grape skin and seeds polyphenols: evidence of their protective effects on endothelial progenitor cells and improvement of their intestinal absorption. Eur J Pharm Biopharm 2102;80(1):176-184.
422. Stefanescu M, et al. Pycnogenol efficacy in the treatment of systemic lupus erythematosus patients. Phytother Res 2001;15:698-704.
423. Gabor M. Anti-inflammatory and anti-allergic properties of flavonoids. Prog Clin Biol Res. 1986;213:471-80.
424. Pinna C, et al. Proanthocyanidins from Vitis vinifera inhibit oxidative stress-induced vascular impairment in pulmonary arteries from diabetic rats. Phytomedicine 2017 Feb;15(25):39-44.
425. Iwasaki Y, et al. The protective and hormonal effects of proanthocyanidin against gastric mucosal injury in wistar rats. J Gastroenterol. 2004;39:831-7.
426. Sharma SC, et al. Pycnogenol inhibits the release of histamine from mast cells. Phytother Res. 2003 Jan;17(1):66-9.
427. Kawai M, et al. Flavonoids and related compounds as anti-allergic substances. Allergol Int. 2007; Jun 56(2):113-23.
428. Santangelo C, et al. Polyphenols, intracellular signalling and inflammation. Ann Ist Super Sanita 2007 43(4):394-405.
429. Terra X, et al. Grape-seed procyanidins act as antiinflammatory agents in endotoxin-stimulated RAW 264.7 macrophages by inhibiting NFkB signaling pathway. J Agric Food Chem 2007;55:4357-65.
430. Duff J. Nutrition for ADHD and Autism in Clinical Neurotherapy: Application of Techniques for Treatment, Academic Press. 2014(14):357–381.
431. Wang R, et al. Phytochemicals as Antidepressants: The Involvement of Serotonin Receptor Function, Stress Resistance and Neurogenesis. Recent Advances in Theories and Practice of Chinese Medicine. Prof. Haixue Kuang (Ed.), ISBN: 978-953-307-903-5 (2012). /li>
432. Xu Y, et al. Antidepressant-like effect of low molecular proanthocyanidin in mice: involvement of monoaminergic system. Pharmacol Biochem Behav. 2010; 94(3):447-53.
433. da Silva GdL, et al. Evidence for dual effects of nitric oxide in the forced swimming test and in the tail suspension test in mice. Cognitive Neuroscience and Neuropsychology 2000;11(17):3699-3702.
434. Bagchi D, et al. Molecular mechanisms of cardioprotection by a novel grape seed proanthocyanidin extract. Mutat Res. 2003; 523-524:87-97.
435. Terra X, et al. Grape-seed procyanidins prevent low-grade inflammation by modulating cytokine expression in rats fed a high-fat diet. J Nutr Biochem. 2009; 20:210-218.
436. Clifton P. Effect of grape seed extract on cardiovascular and endothelial parameters in high risk subjects. Food Australia. 2003; 55:U9-U12.
437. Aldini G, et al. Procyanidins from grape seeds protect endothelial cells from peroxy-nitrite damage and enhance endothelium-dependent relaxation in human artery: new evidences for cardio-protection. Life Sci. 2003; 73:2883-98
438. Quinones M, et al. Beneficial effects of polyphenols on cardiovascular disease. Pharmacol Res. 2013;68(1):125–131.
439. Khurana S, et al. Oxidative stress and cardiovascular health: therapeutic potential of polyphenols. Can J Physiol Pharmacol. 2013;91:198–212.
440. Serafini, M.; Peluso, I.; Raguzzini, A. Flavonoids as antiinflammatory agents. Proc. Nutr. Soc., 2010, 69, 273-278.
441. Sen CK, et al. Regulation of inducible adhesion molecule expression in human endothelial cells by grape seed proanthocyanidin extract. Molecular and Cellular Biochemistry 2001;(216):1–7.
442. Bagchi, D, et al. Cellular Protection with Proanthocyanidins Derived from Grape Seeds. Cellular Protection with Proanthocyanidins Derived from Grape Seeds. Annals of the New York Academy of Sciences, 2001(957):260–270.
443. Wang A, et al. Procyanidins Mitigate Osteoarthritis Pathogenesis by, at Least in Part, Suppressing Vascular Endothelial Growth Factor Signaling. Int J Mol Sci. 2016 Dec; 17(12): 2065.
444. Jhun JY, et al. Grape Seed Proanthocyanidin Extract–Mediated Regulation of STAT3 Proteins Contributes to Treg Differentiation and Attenuates Inflammation in a Murine Model of Obesity-Associated Arthritis. PLoS One. 2013; 8(11): e78843.
445. Heslop CL, et al. Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography. Journal of the American College of Cardiology. 2010;55 (11): 1102–9.
446. Torregrossa AC, et al. Nitric oxide and geriatrics: Implications in diagnostics and treatment of the elderly. J Geriatr Cardiol. 2011 Dec; 8(4): 230–242.
447. Stechmiller, JK, et al. Arginine supplementation and wound healing. Nutr Clin Pract. 2005;20:52-61.
448. Lakatta EG, et al. Myocardial aging: functional alterations and related cellular mechanisms. The American journal of physiology (1982) 242(6):H927-941.
449. Barbarash NA, et al. Nitric oxide and human aging. Adv Gerontol (2012) 2: 71.
450. Chin-Dusting JPF, et al. Effects of in vivo and in vitro L-arginine supplementation on healthy human vessels. J Cardiovasc Pharmacol 1996;28:158–166.
451. Van de Poll MCG, et al. Interorgan amino acid exchange in humans: consequences for arginine and citrulline metabolism. Am J Clin Nutr 2007;85:167–172.
452. Schulman SP, et al. L-Arginine therapy in acute myocardial infarction. The Vascular Interaction with Age in Myocardial Infarction (VINTAGE MI) randomized trial. JAMA 2006;295:58–64.
453. Rainer H. Böger; Asymmetric Dimethylarginine, an Endogenous Inhibitor of Nitric Oxide Synthase, Explains the "L-Arginine Paradox" and Acts as a Novel Cardiovascular Risk Factor, The Journal of Nutrition 2004(Oct)134;10:2842S–2847S.
454. Weseler AR, et al. Pleiotropic benefit of monomeric and oligomeric flavanols on vascular health--a randomized controlled clinical pilot study. PLoS One. 2011;6(12):e28460. doi: 10.1371/journal.pone.0028460. Epub 2011 Dec 8.
455. Zhang X, et al. Age-related alteration in cerebral blood flow and energy failure is correlated with cognitive impairment in the senescence-accelerated prone mouse strain 8 (SAMP8). Neurol Sci. 2013 Nov;34(11):1917-24.
456. Khansari N, et al. Chronic Inflammation and Oxidative Stress as a Major Cause of Age-Related Diseases and Cancer, Recent Pat Inflamm Allergy Drug Discov. 2009 Jan;3(1):73-80.
457. Cai H, et al. Endothelial Dysfunction in Cardiovascular Diseases: The Role of Oxidant Stress. Circulation Research. 2018;87:840-844
458. Drago F, et al. Therapeutic potential of nitric oxide modulation in ocular diseases. Drug News Perspect. 2010 Sep;23(7):430-7.
459. Goldstein IM, et al. Nitric oxide: a review of its role in retinal function and disease. Vision Res. 1996 36(18):2979–2994.
460. Bjarnason I, et al. Blood and protein loss via small-intestinal inflammation induced by non-steroidal anti-inflammatory drugs. Lancet (1987) 330:8561:711-714. doi:10.1016/S0140-6736(87)91075-0.
461. Natividad, JM, et al. Host Responses to Intestinal Microbial Antigens in Gluten-Sensitive Mice. Host Responses to Intestinal Microbial Antigens in Gluten-Sensitive Mice. (2009) PLoS ONE 4(7):e6472. doi:10.1371/journal.pone.0006472.
462. Jenkins R, et al. Increased intestinal permeability in patients with rheumatoid arthritis; A side effect of oral nonsteroidal anti-inflammatory drug therapy. Br J Rheum 26:103-07, 1987
463. Zhang YY, et al. Effect of phosphatidylserine on memory in patients and rats with Alzheimer’s disease. Genet Mol Res. 2015, 14(3):9325-9333.
464. More MI, et al. Positive Effects of Soy Lecithin-Derived Phosphatidylserine plus Phosphatidic Acid on Memory, Cognition, Daily Functioning, and Mood in Elderly Patients with Alzheimer’s Disease and Demetia. Adv Ther 2014, 31:1247-1262.
465. Inoue T, et al. New human clinical trials with phosphatidylserine: teenagers, golfers and other athletes. Food Style 21, 2013, 17(2):63-65.
466.Parker AG, et al. The effects of [soy lecithin-derived phosphatidylserine] on cognitive function, mood and endocrine response before and following acute exercise. J Int Soc Sports Nutr 2011, 8:16.
467. Asano T, et al. The effect of soybean derived phosphatidylserine on the cognitive function of the elderly. Jpn. J. Nutr. Ass. 2005, 24:165–170.
468. Jorissen BL, Brouns F, Van Boxtel MP, Ponds RW, Verhey FR, Jolles J, Riedel WJ: Safety of soy-derived phosphatidylserine in elderly people. Nutr Neurosci. 2002, 5(5):337-343.
469. Hellhammer J, et al. A soy-based phosphatidylserine/ phosphatidic acid complex (PAS) normalizes the stress reactivity of hypothalamus-pituitary-adrenal-axis in chronically stressed male subjects: a randomized, placebo-controlled study. Lipids Health Dis. 2014, 13(1):121.
470. Baumeister J, et al. The influence of phosphatidylserine on cognitive performance and cortical activity after induced stress. Nutr Neurosci 2008, 11 (3):103-110.
471. Hellhammer J, et al. Effects of soy lecithin phosphatidic acid and phosphatidylserine complex (PAS) on the endocrine and psychological responses to mental stress: Stress 2004, 7(2):119-126.
472. Roman GC. Vascular dementia may be the most common form of dementia in the elderly. J Neurol Sci. 2002;203-204:7–10.
473. Heiss W -D, et al. Long-term effects of phosphatidylserine, pyritinol, and cognition training in Alzheimer’s disease.Dementia 1994, 5, 88–98.
474. Jorissen BL, et al. The influence of Soy-derived Phosphatidylserine on Cognition in Age-Associated Memory Impairment. Nutr Neurosci 2001, 4, 121–134.
475. Sinforiani E, et al. Cognitive decline in ageing brain, therapeutic approach with phosphatidylserine. Clin.Trials J. 1987, 24, 115–124.
476. Granata Q, et al. Phosphatidylserine in elderly patients. Clin. Trials J. 1987, 24, 99–103.
477. Puca FM, et al. Exploratory trial of Phosphatidylserine efficacy in mildly demented patients. Clin. Trials J. 1987, 24, 94–98
478. Caffarra P, et al. The Effects of Phosphatidylserine in patients with mild cognitive decline. Clin. Trials J. 1987, 24, 109–114.
479. Allergo L, et al. Oral Phosphatidylserine in elderly patients with cognitive deterioration. An open study. Clin. Trials J. 1987, 24, 104–108.
480. Lombardi GF. Terapia farmacologia con fosfatidil serina in 40 pazienti ambulatoriali con sindrome demenziale senile. Minerva Med. 1989, 80, 599–602.
481. Rabboni M, et al Neuroendocrine and behavioural effects of phosphatidylserine in elderly patients with abiotrophic or vascular dementia or mild depression. Clin. Trials J. 1990, 27, 230–240.
482. Guzik T, et al. Nitric oxide and superoxide in inflammation. Journal of physiology and pharmacology 54 (2003): 469-487.
483. Coleman JW. Nitric oxide: a regulator of mast cell activation and mast cell-mediated inflammation. Clin Exp Immunol. 2002 Jul; 129(1): 4–10.
484. Sorond FA, et al. Neurovascular coupling, cerebral white matter integrity, Neurology. 2013 Sep 3; 81(10):904–909.
485. Beckman JA, et al. Arginine impairs endothelial and executive function in older subjects with cardiovascular risk. J Am Soc Hypertens. 2018 Oct; 12(10):723–731.
486. Liu F, et al. Pycnogenol protects vascular endothelial cells from beta-amyloid-induced injury. Biol Pharm Bull. 2000 Jun;23(6):735-7.
487. Ansari MA, et al. Protective effect of Pycnogenol in human neuroblastoma SH-SY5Y cells following acrolein-induced cytotoxicity. Free Radic Biol Med. 2008 Dec 1;45(11):1510-9.
488. Luzzi R, et al. Pycnogenol supplementation improves cognitive function, attention and mental performance in students. Panminerva Med. 2011 Sep;53(3 Suppl 1):75-82
489. Peng QL, et al. Pycnogenol protects neurons from amyloid-beta peptide-induced apoptosis. Brain Res Mol Brain Res. 2002 Jul 15;104(1):55-65.
490. Ishrat T, et al. Effects of Pycnogenol and vitamin E on cognitive deficits and oxidative damage induced by intracerebroventricular streptozotocin in rats. Behav Pharmacol. 2009 Oct;20(7):567-75.
491. Ryan J, Croft K, Mori T, et al. An examination of the effects of the antioxidant Pycnogenol on cognitive performance, serum lipid profile, endocrinological and oxidative stress biomarkers in an elderly population. J Psychopharmacol. 2008 Jul;22(5):553-62
492. Wang, YJ. Clearance of amyloid-beta in Alzheimer’s disease; to understand the pathogenesis and develop potential therapies in animal model. A thesis submitted in total fulfilment of the requirements of the degree of doctor of philosophy by Yan-Jiang Wang, Doctor of Medicine (Neurology) Master of Medicine (Preventive Medicine) Bachelor of Medicine (Clinical Medicine), Department of Human Physiology, Centre for Neuroscience, School of Medicine, Flinders University, Adelaide, South Australia; flex.flinders.edu.au; 2009 Nov.
493. Trebaticka J, et al. Psychiatric Disorders and Polyphenols Can They Be Helpful in Therapy? Oxidative Medicine and Cellular Longevity, 2015:248529.
494. Trebaticka J, et al. Effect of polyphenolic extract, pycnogenol, on the level of 8-oxoguanine in children suffering from attention deficit/hyperactivity disorder. Free Radical Research, 2009 40:9, 1003-1010.
495. Yoo DY, et al. Grape seed extract enhances neurogenesis in the hippocampal dentate gyrus in C57BL/6 mice. Phytother. Res. 2011 25: 668-674.
496. Ahn S-H, et al. Grape seed proanthocyanidin extract inhibits glutamate-induced cell death through inhibition of calcium signals and nitric oxide formation in cultured rat hippocampal neurons. BMC Neurosci, 2011 12:78.
497. Xia R, et al. Neuroprotective effects of pycnogenol against oxygen-glucose deprivation/reoxygenation-induced injury in primary rat astrocytes via NF-κB and ERK1/2 MAPK pathways. Cell Physiol Biochem 2017;42:987–998.
498. Feng Y, et al. Grape seed extract given three hours after injury suppresses lipid peroxidation and reduces hypoxic-ischemic brain injury in neonatal rats. Pediatr Res 2007 61, 295–300.

References for Flavay® Articles

U.S. AND INT'L PATENTS · Clinically Proven Since 1947

Customer Service: 1-800-200-1203 or 210-481-0067